XCancer

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

Description:

This study assess the Diagnostic Performance of \[18F\]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer

Sponsor:

Advanced Biochemical Compounds

Phase:

Phase 3

Contacts:

Alexander Hoepping, Dr. (CONTACT)

cd@abx.de

+49 3528 4041 60

Government Study Link:

NCT06122584 - Click here to see study on

ClinicalTrials.gov

PSMA-1007

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Inclusion
  • The patient has at least high-risk disease as defined by the NCCN guidelines (version 1.2023). That is, the presence of any one or more of the following:
  • Clinical category T3a or greater,
  • Serum PSA level greater than 20 ng/ml.
  • The patient has newly diagnosed, biopsy-proven, clinically localized prostate adenocarcinoma, and curative prostatectomy with extended pelvic lymph node dissection is his preferred course of treatment.
  • Overall ISUP grade group 4 or 5,
Exclusion
  • Patients for whom radical prostatectomy is not clinically appropriate or the patient is otherwise unlikely to undergo radical prostatectomy with extensive pelvic lymph node dissection.